Search results
Showing 571 to 585 of 699 results for end of life care
Direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implant (IPG795)
Evidence-based recommendations on direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implant. This involves inserting a metal implant through the skin and into the centre of the bone of the stump and attaching a prosthetic limb to it.
View recommendations for IPG795Show all sections
NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
This guideline covers recognising and responding to abuse and neglect in children and young people aged under 18. It covers physical, sexual and emotional abuse, and neglect. The guideline aims to help anyone whose work brings them into contact with children and young people to spot signs of abuse and neglect and to know how to respond. It also supports practitioners who carry out assessments and provide early help and interventions to children, young people, parents and carers.
Find out more about NICE technology appraisals advisory committee D members
secretions:- In people considered to be in the last few hours and days of life, are antisecretory anti-muscarinic drugs (used alongside...
NICE has developed a medtech innovation briefing (MIB) on IQoro for stroke-related dysphagia .
NICE has developed a medtech innovation briefing (MIB) on Butterfly iQ+ for diagnostic ultrasound imaging .
Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Prognostic Index an accurate predictor of survival in people with MND under NHS care in England and/or Wales? Any explanatory notes(if...
Etelcalcetide for treating secondary hyperparathyroidism (TA448)
Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.
mesh complications, it is important to think about your whole quality of life now and what you hope to gain from treatment. Treatment...
The social care guidance manual
Show all sections
- 1 Introduction
- 2 The scope
- 3 The Guidance Development Group
- 4 Developing review questions and planning the systematic review
- 5 Identifying the evidence: literature searching and evidence submission
- 6 Reviewing the evidence
- 7 Incorporating economic evaluation
- 8 Linking social care guidance to other NICE guidance
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)
Evidence-based recommendations on danicopan (Voydeya) with ravulizumab (Ultomiris) or eculizumab (Soliris) for paroxysmal nocturnal haemoglobinuria in adults with residual haemolytic anaemia.